WFH Humanitarian Aid Program continues to make care and treatment possible for bleeding disorders community

For many people with hemophilia around the world, access to care and treatment can be a considerable daily challenge. Through the expanded WFH Humanitarian Aid Program, increased multi-year donations now means it is possible for people with bleeding disorders in the developing world to have continued access to treatment for emergency situations, acute bleeds, corrective surgeries, and also prophylaxis for young children.

In 2018 alone, over 18,400 patients received treatment through the WFH Humanitarian Aid Program. This exceeds the total number of patients receiving treatment through the program from 1996 to 2016. This is as a direct result of the significant level of donations provided by Sanofi Genzyme, and Sobi, with the visionary commitment of 500 million international units of clotting factor concentrates treatment products, over 5 years, along with their substantial financial support for the operational needs of this program.

Through this contribution to the WFH Humanitarian Aid Program, local healthcare professionals reported that more than 18,400 people with hemophilia, in 62 countries, were treated in 2018. Significant outcomes occurred during the past year: 1,546 people have been put on prophylactic treatment since the start of the expansion of the program; over 58,458 acute bleeds were treated last year; and more than 685 surgeries were completed in 2018.

“Not only is the sheer volume of surgeries a big step forward for the facility, but the variety of performed surgeries is also important, because it has allowed doctors to broaden their experience, become better at their jobs, and consequently, provide better care for patients,” said Vikash Goyal, President of the Haemophilia Federation of India.

As the cost of treatment is prohibitively expensive for the majority of those affected with a bleeding disorder, donations of this magnitude means a complete shift in how patients are now treated in developing countries. The reality is that limited access to diagnosis and treatment in many developing countries means that people with severe hemophilia in these areas often do not survive to adulthood. The demonstrated results of the WFH Humanitarian Aid Program are leading to a change in this reality.

Assad Haffar, WFH Director, Humanitarian Aid

“The WFH Humanitarian Aid Program really does change lives. It makes it possible for children go to school for the first time and for parents to go back to work and support their families.”

To support healthcare providers that received donated treatment, the WFH Humanitarian Aid Program also provides a range of integrated care development training programs to ensure the local infrastructure and medical expertise are available to optimize and appropriately use donated products.

Continued demonstrable leadership will give hope to those who had no realistic option for treatment before. We will keep working with all our global partners to come together to further strengthen the success of the WFH Humanitarian Aid Program.


The visionary contribution from Sanofi Genzyme and Sobi to the WFH Humanitarian Aid Program translates into 500 million IUs over five years (2015-2020). Sanofi Genzyme and Sobi also make ongoing substantial financial contributions to support the logistics of product delivery and training of providers and patients in humanitarian aid countries. Furthermore, the eight-year commitment (2014-2021) from Grifols totaling 200 million IUs, along with a ten-year commitment (2009-2018) from CSL Behring for a total of 22 million IUs, and the three-year agreement (2017-2019) with Green Cross for 6 million IUs, allows for a more predictable and sustainable flow of humanitarian aid donations to the global community.